Baseline characteristics in the placebo / bee venom groups.

<p>Baseline characteristics in the placebo / bee venom groups.</p

Main results in the placebo / bee venom groups.

<p>Main results in the placebo / bee venom groups.</p

Kinetics of bee venom specific antibodies.

<p>The sample at day -60 was taken at the pre-screening, the first bee venom injection was done at day 0 and the first sample after at day 30. Diamonds are for specific IgE (kU/L) and the squares for specific IgG4 (mg/L). (A)kinetics of specific IgE production for all patients; (B) kinetics for specific IgE and IgG4 for a single representative patient.</p

Bee Venom for the Treatment of Parkinson Disease – A Randomized Controlled Clinical Trial - Fig 2

<p>Evolution of the differences of UPDRS III (A), II (B) and total scores (C) with baseline over the 11 month study period in the placebo and bee venom groups.</p

Study Flowchart.

<p>Study Flowchart.</p

Comparison of [123I]-FP-CIT binding potential changes between V2 and V13 in the placebo / bee venom groups.

<p>Comparison of [123I]-FP-CIT binding potential changes between V2 and V13 in the placebo / bee venom groups.</p

Additional file 2: Table S1. of Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort

Statistical significance of two-by-two cognitive categories comparisons of baseline characteristics distributions: the MEMENTO cohort. Table S2. Baseline characteristics by age group and sex: the MEMENTO cohort. Table S3. Association between baseline characteristics and number of copies of ε4 allele of APOE genotype: the MEMENTO cohort. (DOCX 47 kb

Additional file 1: of Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort

Description of neuropsychological battery. (DOCX 29 kb